From

Institution

Field

Type

Open access only Cited by patents (Lens) Include non-Aachen papers (citing/cited)

Reset

Papers matching “phase locking” 15

Sort: Relevance Cited Newest Oldest Fwci Patents ⇩ CSV

Not finding it? Sign in to also search OpenAlex live.

BOLD-CSF dynamics assessed using real-time phase contrast CSF flow interleaved with cortical BOLD MRI
2024 Fluids and Barriers of the CNS article Medicine Advanced MRI Techniques and Applications Open access

Emiel C. A. Roefs, Ingmar Eiling, Jeroen de Bresser, Matthias J.P. van Osch, Lydiane Hirschler

18

citations
Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial
2020 Blood article Medicine Chronic Myeloid Leukemia Treatments

Tim H. Brümmendorf, Jörge E. Cortes, Dragana Milojković, Carlo B Gambacorti-Passerini, Richard E. Clark, Philipp D. le Coutre, +13 more

31

citations
P719: EFFICACY AND SAFETY OF BOSUTINIB IN LATER-LINE PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A SUB-ANALYSIS FROM THE PHASE 4 BYOND TRIAL
2022 HemaSphere article Medicine Chronic Myeloid Leukemia Treatments Open access

Carlo B Gambacorti-Passerini, Tim H. Brümmendorf, Thomas Ernst, Eric P. Leip, Simon Purcell, Andrea Viqueira, +3 more

0

citations
Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5101) in Relapsed/Refractory NHL: Results from the Phase 1 Atalanta-1 Trial
2023 Blood conference-abstract Medicine CAR-T cell therapy research

Marie José Kersten, Kirsten Saevels, Yves P. Beguin, Joost S.P. Vermaat, Nadia Verbruggen, Maike Spoon, +5 more

6

citations
Efficacy and safety of bosutinib in later-line patients (pts) with chronic myeloid leukemia (CML): A sub-analysis from the phase 4 BYOND trial.
2022 Journal of Clinical Oncology conference-abstract Medicine Chronic Myeloid Leukemia Treatments

Carlo B Gambacorti-Passerini, Tim H. Brümmendorf, Thomas Ernst, Eric P. Leip, Simon Purcell, Andrea Viqueira, +3 more

2

citations
Single-pulse stimulation of cerebellar nuclei stops epileptic thalamic activity
2021 Brain stimulation article Medicine Epilepsy research and treatment Open access

Oscar H. J. Eelkman Rooda, Lieke Kros, Sade J. Faneyte, Peter J. Holland, Simona V. Gornati, Huub J. Poelman, +5 more

31

citations
Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial
2021 Blood conference-abstract Medicine Chronic Myeloid Leukemia Treatments

Carlo B Gambacorti-Passerini, Tim H. Brümmendorf, Elisabetta Abruzzese, Kevin R. Kelly, Vivian G. Oehler, Valentín García‐Gutiérrez, +8 more

7

citations
Efficacy and Safety of Bosutinib Vs Imatinib By Charlson Comorbidity Index in Newly Diagnosed Patients with Chronic Myeloid Leukemia
2022 Blood article Medicine Chronic Myeloid Leukemia Treatments

Michael W. Deininger, Tim H. Brümmendorf, Jeffrey Howard Lipton, Dragana Milojković, Leif Stenke, Eric P. Leip, +3 more

0

citations
Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men
2021 JAMA Oncology article Medicine Male Breast Health Studies Open access

Mattea Reinisch, Sabine Seiler, Tanja Hauzenberger, Axel Kamischke, Sabine Schmatloch, Hans-Joachim Strittmatter, +14 more

50

citations
Field evaluation of a point-of-care triage test for active tuberculosis (TriageTB)
2023 BMC Infectious Diseases conference-abstract Medicine Tuberculosis Research and Epidemiology Open access

Tracy Richardson, Bronwyn Smith, Stephanus T. Malherbe, Jane Alexandra Shaw, Firdows Noor, Candice MacDonald, +44 more

14

citations
Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial
2020 Blood article Medicine Chronic Myeloid Leukemia Treatments

Jörge E. Cortes, Philipp D. le Coutre, Carlo B Gambacorti-Passerini, Henrik Hjorth‐Hansen, Pia Raanani, Valentín García‐Gutiérrez, +5 more

5

citations
Bosutinib (BOS) in newly diagnosed chronic myeloid leukemia (CML): Gastrointestinal (GI), liver, effusion, and renal safety characterization in the BFORE trial.
2022 Journal of Clinical Oncology conference-abstract Medicine Chronic Myeloid Leukemia Treatments

Jörge E. Cortes, Dragana Milojković, Carlo B Gambacorti-Passerini, Valentín García‐Gutiérrez, Michael J. Mauro, Eric P. Leip, +3 more

2

citations
P717: BOSUTINIB IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: GASTROINTESTINAL, LIVER, EFFUSION AND RENAL SAFETY CHARACTERIZATION IN THE BFORE TRIAL
2022 HemaSphere article Medicine Chronic Myeloid Leukemia Treatments Open access

Jörge E. Cortes, Dragana Milojković, Carlo B Gambacorti-Passerini, Valentín García‐Gutiérrez, Michael J. Mauro, Eric P. Leip, +3 more

0

citations
The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia.
2021 Journal of Clinical Oncology conference-abstract Medicine Chronic Myeloid Leukemia Treatments

Tim H. Brümmendorf, Jörge E. Cortes, Lambert Busque, Carlo B Gambacorti-Passerini, Leif Stenke, Andrea Viqueira, +3 more

5

citations
Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib.
2021 Journal of Clinical Oncology conference-abstract Medicine Chronic Myeloid Leukemia Treatments

Michael W. Deininger, Tim H. Brümmendorf, Dragana Milojković, Francisco Cervantes, Françoise Huguet, Andrea Viqueira, +3 more

5

citations

15 results